share_log

Relief Therapeutics' Subsidiary Posts Early Data For Nasal Spray COVID-19 Treatment

Relief Therapeutics' Subsidiary Posts Early Data For Nasal Spray COVID-19 Treatment

緩解治療公司的子公司發佈了鼻噴劑新冠肺炎治療的早期數據
Benzinga Real-time News ·  2021/10/27 09:07
  • Relief Therapeutics Holding SA's (OTC:RLFTF) wholly-owned subsidiary, APR Applied Pharma Research SA, has reported interim results from its clinical trial of nasal spray Sentinox in COVID-19.
  • Relief also reported that data from the study suggest that Sentinox could effectively reduce the SARS-CoV-2 viral load at the level of the nasal mucosa.
  • The interim analysis, based on 30 patients, showed that all patients treated with Sentinox tested negative for SARS-CoV-2 by the end of the study period (Day 21). 
  • By contrast, one out of 10 patients in the control group was still positive by Day 21. 
  • A post-market, confirmatory, interventional, randomized, placebo-controlled study is expected to enroll a total of 57 patients. 
  • The study will assess the efficacy and safety of Sentinox spray in reducing viral load in the upper respiratory airways of recently infected SARS-CoV-2 individuals.
  • Sentinox is an acid-oxidizing solution (AOS) containing hypochlorous acid at 0.005%. 
  • The device is intended for irrigation, cleaning, and moistening nasal cavities.
  • Related: Why NRX Pharmaceuticals (NRXP) Stock Is Moving Friday?
  • Price Action: RLFTF stock closed 6.28% higher at $0.091 on Tuesday.
  • 救濟治療公司持有SA‘s(場外交易代碼：RLFTF)全資子公司，應用藥學研究協會，已經報告了其在新冠肺炎進行的鼻噴劑Sentinox臨牀試驗的中期結果。
  • Release還報道説，研究數據表明，Sentinox可以有效地降低鼻黏膜水平的SARS-CoV-2病毒載量。
  • 這項基於30名患者的中期分析顯示，在研究結束時(第21天)，接受Sentinox治療的所有患者的SARS-CoV-2檢測結果均為陰性。
  • 相比之下，對照組中每10名患者中就有一名在第21天時仍呈陽性。
  • 一項上市後的驗證性、幹預性、隨機化、安慰劑對照研究預計將招募57名患者。
  • 這項研究將評估Sentinox噴霧劑在降低最近感染SARS-CoV-2患者上呼吸道病毒載量方面的有效性和安全性。
  • 森替諾是一種含有0.005%次氯酸的酸性氧化液。
  • 該設備用於沖洗、清潔和潤濕鼻腔。
  • 相關： 為什麼NRX製藥公司(NRX PharmPharmticals)的股票週五會上漲？
  • 價格行動：RLFTF股票週二收高6.28%，報0.091美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論